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Abstract
A phenome-wide association study of variants in genes in the Th17 and IL-17 pathway was
performed using self-reported phenotypes and genetic data from 521,000 research partici-
pants of 23andMe. Results replicated known associations with similar effect sizes for auto-
immune traits illustrating self-reported traits can be a surrogate for clinically assessed
conditions. Novel associations controlling for a false discovery rate of 5% included the asso-
ciation of the variant encoding p.Ile684Ser in TYK2 with increased risk of tonsillectomy,
strep throat occurrences and teen acne, the variant encoding p.Arg381Gln in IL23R with a
decrease in dandruff frequency, the variant encoding p.Asp10Asn in TRAF3IP2 with risk of
male-pattern balding, and the RORC regulatory variant (rs4845604) with protection from
allergies. This approach enabled rapid assessment of association with a wide variety of
traits and investigation of traits with limited reported associations to overlay meaningful
phenotypic context on the range of conditions being considered for drugs targeting this
pathway.
Introduction
T helper (Th) 17 cells produce the cytokine interleukin 17 (IL-17) and play a role in multiple
autoimmune and infectious diseases. There are promising drugs, including several anti IL-17
or anti IL-17 receptor (IL-17R) antibodies, targeting the Th17 and IL-17 pathway for dermatol-
ogy and autoimmune diseases, some of which have been recently approved and others that are
in development [1]. The anti IL-17 antibodies were efficacious for psoriasis but seemed to
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increase both disease activity and adverse events including infection when investigated in
patients with active Crohn’s disease [CD] [2, 3]. A study to identify novel associations for
genes in this pathway has the potential to suggest new indications and highlight possible safety
concerns for existing and emerging drugs [4]. This is particularly useful in the drug develop-
ment context since genetically supported targets are demonstrated to have increased success
rates in clinical development [5].
In the last 10 years, the genetic contribution to common disease has been investigated by
performing increasingly large genome wide association studies (GWAS), whereby polymor-
phisms along all chromosomes are tested for association with a trait of interest. GWAS results
have provided a growing catalog of the genetic loci that play a role in disease pathogenesis.
Identifying causal variants is difficult and usually more work is required to identify the mecha-
nism by which a variant influences a clinical trait [6]. An alternate approach which can provide
insight into possible biological disease mechanisms is a phenome-wide association study (Phe-
WAS), whereby a particular variant is studied for association with a wide variety of traits to
profile the phenotypic effects of a gene variant. This approach is relevant to drug discovery
when a variant is known to have a functional effect and the available traits include conditions
which have not been previously studied, since there is focus on anticipating the effects of mod-
ulating the gene products as drug targets. Denny et al., [7] applied the PheWAS paradigm
using electronic medical records (EMRs) to study the relationships between genetic variants
and multiple traits in 13,835 participants. In the present study, we used the approach with a
much larger database (521,000) of self-reported health histories from research participants of
the genetics company, 23andMe, to investigate the relationship between variants in genes
from the Th17 and IL-17 pathway to provide insight into the functional consequences of mod-
ulating the proteins encoded by these genes.
We selected seven variants from seven genes known to be in the Th17 and IL-17 pathway,
for PheWAS analysis. We included variants with established GWAS associations and/or those
predicted to have functional consequences. We evaluated associations across the selected gene
variants to look for common patterns of association. Selected variants were also compared
with previous association reports for autoimmune diseases, to evaluate how genetic analysis of
these self-reported phenotypes compare to more traditional case-control study results. Results
for two of the variants (encoding p.Arg381Gln in IL23R and p.Ile684Ser in TYK2) which were
included in a PheWAS of 1,358 EMR-derived traits evaluated in 13,835 European-ancestry
individuals from five sites of the Electronic Medical Records and Genomics (eMERGE) net-
work (7) were compared with the results from this study. Lastly, PheWAS results from each
variant were more comprehensively assessed, evaluating each gene from a drug target perspec-
tive. While this study focused on only 7 genes within the pathway, the results provide insight
into the use of PheWAS in drug discovery research.
Results
Variant selection and association analyses
We evaluated variants in 57 genes (Wikipathways www.wikipathways.org) from the Th17 and
IL-17 pathway, denoted IL-17 signaling pathway in homo sapiens (S1 Table) and identified
seven variants either known or predicted to be functional, or associated with multiple common
conditions with minor allele frequencies (MAF) greater than 0.5%. S2 Table lists the seven var-
iants along with associations previously reported for each variant [5]. Genotype data for these
seven variants were available from genome wide array genotyping data and any missing values
were imputed. Each variant was tested for association with 1254 health-related traits, derived
from self-reported phenotype data. A total of 521,000 study participants with greater than 97%
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European ancestry (determined through analysis of local ancestry) with phenotype data for the
questions of interest were included. Analyses were adjusted for age, gender, and the top five
ancestry principal components to account for residual population structure. The false discov-
ery rate (FDR) was controlled at 5% over analyses for all 7 variants [8]. We report FDR q-val-
ues throughout the paper, except when compared to previously reported p-values. Power was
estimated across a variety of traits (with widely differing sample sizes) for the MAFs observed
for all variants to assist with interpretation of results.
Association results
Association results for all seven variants with all 1254 traits are shown in Fig 1, S3 Table lists all
results significant at 5% FDR and S4 Table lists all results. For four variants, the IL23R mis-
sense variant encoding p.Arg381Gln (rs11209026; c.1142G>A; MAF = 0.07), the RORC regu-
latory variant (rs4845604; c.70+225C>T; MAF = 0.14), the TRAF3IP2missense variant
encoding p.Asp10Asn (rs33980500; c.28G>A; MAF = 0.08), and the TYK2missense variant
encoding p.Ile684Ser (rs12720356; c.2051T>G; MAF = 0.09), we observed a large number of
highly significant associations (six or more per variant at 5% FDR), including traits with both
previously known and novel associations. Fig 2 shows a heat map of association statistics, for
all traits associated with at least one variant at 5% FDR. A cluster of autoimmune traits (ulcera-
tive colitis, psoriasis, inflammatory bowel disease [IBD]—Crohn’s disease or ulcerative colitis)
have associations for variants in IL23R and TRAF3IP2 genes. Beyond the associations with
autoimmune traits, the variants in IL23R, RORC, TRAF3IP2 and TYK2 seem to have variant
specific, rather than pathway-related, association patterns. For these four variants, and also for
the IL17RB nonsense variant encoding p.Gln484Stop (rs1043261; c.1450C>T; MAF = 0.08),
we identified, at 5% FDR, a number of previously unreported associations, albeit some at bor-
derline significance levels, which we discuss further below. We did not observe any significant
associations for the IL17A promoter variant (rs2275913; c.-197G>A; MAF = 0.35) or the
IL17F missense variant encoding p.His161Arg (rs763780; c482A>G; MAF = 0.05). These neg-
ative results are consistent with the relatively weaker a priori evidence for either large func-
tional effects or phenotypic associations for these two variants, but are also consistent with a
possible functional effect but lower power for the IL17F variant encoding p.His161Arg due to
the lower MAF. Fig 2 shows that, for some traits, the IL17F variant encoding p.Asp10Asn may
have comparable effect sizes to other variants evaluated here (shown by size of the circles),
although at lower statistical significance levels (shown by color intensity). These results pro-
vide evidence that the IL17A variant we selected is unlikely to have a large effect on the human
traits studied (upper bounds shown by outer circle size in Fig 2), likely due to insufficient func-
tional impact. Overall, these results suggest that genes involved in the Th17 and IL-17 pathway
have variable and heterogeneous mechanistic influences on a range of human disease
phenotypes.
Comparison to GWAS results
We investigated similarities and differences of the current PheWAS results, with association
results available in the literature that were based on clinician assessment or validated diagnos-
tic instruments. Fig 3 and S5 Table compare the association statistics for Crohn’s disease,
IBD, psoriasis, psoriatic arthritis and eczema. Of fourteen previously reported associations
summarized in Fig 3, nine were previously associated with genome-wide significance levels
(p5.0×10−8). For all fourteen of the previously reported associations, the odds ratios for this
dataset were in the same direction as the previously reported associations although we
observed significantly different (p<0.05) effect estimates for 7 of the 14 associations (S6
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Table). These differing estimates could be attributed to factors such as differences in sample
size, phenotype definitions, patient demographics or to the winner’s curse [9].
Power analyses
For PheWAS studies, power will be highly variable due to the varying sample sizes across phe-
notypes, precision of the phenotype and allele frequency of the variant. To support interpreta-
tion, we performed a comprehensive power analysis of traits, for the given allele frequencies.
S7 Table summarizes results from an analysis of power across a variety of traits including the
minimum odds ratio (OR) or effect size (β), in response standard deviations per allele, for
binary or continuous traits, respectively, for each variant where there is 80% power to identify
an additive effect assuming the given allele frequency, sample size and α = 0.0002, the p-value
threshold which empirically corresponds to the FDR cut-off of 5%. No adjustment to account
for precision of the phenotype was made. For the variants studied, there is 80% power to iden-
tify small effects (OR>1.15; β>0.06) for 26–71% of the traits across the MAF range, moderate
effects (OR>1.5; β>0.11) for 87–95% of the traits and large effects (OR>2; β>0.15) for nearly
90% of the traits (S8 Table). Review of the power results by trait category highlights that there
is 80% power to detect moderate (OR>1.5; β>0.11) or large effects (OR>2; β>0.15) for more
than 75% of the traits within all trait categories except drug side effects, drug efficacy and Par-
kinson’s disease related traits. However, there is 80% power to detect small effects (OR>1.15;
Fig 1. PheWAS results for variants in seven genes. False Discovery Rate q-values for 1254 traits are plotted for
each variant evaluated. Closed circles depict association of the minor allele with increased risk of the conditions and
open circles with protection from the conditions. Horizontal dashed lines indicate the q = 0.05 FDR threshold.
https://doi.org/10.1371/journal.pone.0186405.g001
Fig 2. Heat map of selected PheWAS associations. Associations are shown for each variant with each trait, for the set of all traits that had association with
any -variant at 5% FDR. For each association, black circles are drawn with area proportional to the effect size point estimate (inner circle) and 95% upper
confidence limit (outer circle), scaled relative to the maximum within each trait. The inner circle is colored according to the effect direction (blue to red) and
significance (color scale according to association Z score, with corresponding q value cut-offs shown in the legend). Traits and [variants] are ordered using
hierarchical clustering on Euclidean distances between columns [and rows] of the association Z score matrix.
https://doi.org/10.1371/journal.pone.0186405.g002
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β>0.06) for 65% of the traits only within the trait categories of cognition, sleep, infection, life-
style, sensation, longevity and personality.
Interpretation of results by variant
The IL23R gene is involved in Th17 regulation and regulates IL-17 production [10]. The
IL17-induced Th17 effector function is impaired in the presence of rs11209026 encoding p.
Arg381Gln. This minor allele encoding the glycine residue has also been previously associated
with twofold protection against psoriasis and threefold protection against Crohn’s disease
[10]. Consistent with previous reports, in this study, the minor allele was associated with
protection from Crohn’s disease (OR = 0.53; q = 6.63x10-28), IBD (OR = 0.67; q = 8.0x10-31),
psoriasis (OR = 0.82; q = 7.64x10-20), and a composite of 25 auto-immune conditions (OR =
0.88; q = 9.37x10-20). The minor allele was also associated with traits likely driven by these
disease associations: in participants reported as taking anti-TNFα medications (OR = 0.72;
q = 3.92x10-8) and in patients reported as taking prednisone or other steroid medications
(OR = 0.95; q = 0.026). We also observed a novel and highly significant association with a
Fig 3. Association and literature results. Summary of association statistics for study results and previously reported associations for Crohn’s disease, IBD,
psoriasis, psoriatic arthritis and eczema.
https://doi.org/10.1371/journal.pone.0186405.g003
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decrease in dandruff frequency (β = -0.08; q = 6.61x10-7). This is unlikely to be driven by other
trait associations since dandruff frequency was not significantly correlated with the other asso-
ciated traits (S1 Fig). The variant was included in a previously reported PheWAS analysis
which failed to identify any statistically significant associations using a Bonferroni threshold of
p<0.05/1358 = 3.7x10-5 [7].
The RORγT transcript of the RORC gene is an important transcription factor in Th17 dif-
ferentiation. The rs4845604 variant is hypothesized to have a regulatory effect on expression
and may be associated with reduced levels of the transcript. This variant was the only common
variant in RORC with a previously reported genetic association–with IBD [11]. The q-value for
association of the rs4845604 with IBD was q = 0.18 which failed to meet the q<0.05 threshold.
We observed an association with the minor allele (A) of this variant with decreased hair curl
(β = -0.09; q = 9.92x10-31). The variant is 261kb from rs17646946 (MAF = 0.24; r2 = 0.02 and
D’ = 0.20 with rs4845604) within the TCHH gene, which has been associated with hair curl in
multiple studies [12, 13]. The Eriksson et al paper [12] studied participants that were included
in this PheWAS. The association of rs4845604 with hair curl is likely to be novel, but further
conditional analyses would be required to determine if this signal and previously report associ-
ations implicating TCHH may tag the same underlying genetic effect. We observed associa-
tions of the minor allele with protection from multiple allergies including dog (OR = 0.92;
q = 0.019) and any animal (OR = 0.95; q = 0.042), and with subjects receiving medications for
asthma or other lung conditions (OR = 0.95; q = 0.008). Additionally, there were associations
with q-values just above the 0.05 threshold with protection from mold allergy (OR = 0.95;
q = 0.062), any food allergy (OR = 0.94; q = 0.069) and grasses allergy (OR = 0.96; q = 0.072).
The minor allele was not associated with protection from asthma (OR = 0.97; q = 0.22). The
associated traits showed high levels of correlation between different allergy traits and between
allergy and the asthma related traits (S1 Fig).
TRAF3IP2 encodes ACT1, a signaling adaptor involved in the regulation of adaptive immu-
nity. The variant, rs33980500, encoding p.Asp10Asn has been shown to prevent ACT1 from
interacting with TRAF6, suggesting that this variant may modulate downstream signals of dif-
ferent crucial immunoreceptors through altered TRAF interactions [14]. The variant had been
previously reported as associated with IBD [11, 15], psoriasis [16], and psoriatic arthritis [14].
Only psoriasis (OR = 1.09; q = 0.0019) and IBD (OR = 1.11; q = 0.042) were found to have a
significant association in this dataset compared to previously reported odds ratios (OR = 1.53;
95% CI [1.41,1.67]) for psoriasis [16] and (OR = 1.15; 95% CI [1.09,1.22]) for IBD [15]. Despite
previous reports of an association with psoriatic arthritis (OR = 1.95; p = 1.13x10-20) [14], and
80% power to detect an OR of 1.29 in this dataset, the association with psoriatic arthritis is
non-significant. Significant associations were observed for protection from frequent nose
bleeds (OR = 0.87; q = 0.0063) and severe acne (OR = 0.93; q = 0.022), for green eye color as
measured on a blue versus green scale (β = -0.04; q = 0.026), for risk of male pattern balding
before age 40 (OR = 1.17; q = 0.021) and male pattern balding (analyzed using survival analysis
—Hazard Ratio = 1.09; q = 0.042). Further evaluation of the association of this variant and
acne vulgaris in 1893 cases and 5132 controls (imputation r2 = 0.99 with p = 0.51) did not rep-
licate the observed results [17, 18]. A look-up in an association analysis of male pattern balding
in CoLaus including 578 cases and 547 controls demonstrated that this variant was associated
with male pattern balding (OR = 1.34, p = 0.02; 95% CI of [1.05, 1.72]) with imputation r2 of
0.91 [19]. Review of a published GWAS using 23andMe database for blue versus green eye
color (31,037 cases and 30,741 controls) identified association with the G allele of rs13200059
(OR = 1.26; 95% CI [1.18, 1.35]; p = 2.7x10-11). The credible set for the region includes the
TRAF3IP2 gene. The effector gene in this locus is more likely to be SLC16A10which is an aro-
matic amino acid transporter where the drosophila orthologue of this gene, KAR, is known to
Phenome-wide association study of Th17 IL-17 pathway genes
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be involved in visual pigmentation (33). Review of Pearson correlation coefficients between
associated traits (S1 Fig) highlighted correlation within the related male pattern baldness traits
and within the related eye color traits but not between the trait groupings suggesting that these
associations may represent true pleiotropy.
TYK2 is a member of the Janus kinase (JAK) family of proteins that mediates signaling
downstream of several cytokine receptors and intercellular adhesion molecule genes [20].
This gene contains a number of common coding variants including the missense variants
rs34536443, encoding p.Pro1104Ala, and rs12720356 encoding p.Ile684Ser. We selected the
rs12720356 variant for study as it was the only missense variant previously predicted to be del-
eterious with MAF greater than 5% with previous disease association reports: Crohn’s disease
[11] and psoriasis [21]. A recent analysis of the functional impact of variants in the TYK2 gene
established that minor allele homozygosity at the rs34536443 SNP drives a near-complete loss
of TYK2 function which impairs type I IFN, IL-12 and IL-23 signaling whereas rs12720356
does not have similar biological effects [22]. Analysis of publicly available eQTL data suggests
that the rs1270356 or the rs5030390 variant that is in linkage disequilibrium with it, may have
an effect on ICAM1 expression in stimulated CD14+ monocytes suggesting the ICAM1 gene
which may explain why rs34536443 confers protection from multiple diseases while more het-
erogeneous effects were noted for rs1270356 [22]. We observed significant associations
between this variant and increased weight (β = 0.88; q = 4.10x10-5) and height (β = 0.06; q =
0.0011) as well as associations with risk of tonsillectomy (OR = 1.06; q = 0.0061), IBD (OR =
1.12; q = 0.0061), more severe acne as a teenager (β = 0.03; q = 0.034), strep throat occurrences
(β = 0.04; q = 0.038), and BMI (β = 0.09; q = 0.039). None of these associations were replicated
in a PheWAS of 13,835 European-ancestry individuals which included the variant, although
the case counts for tonsillitis, IBD and acne related phenotypes (S9 Table) were all less than
262 [7]. The associations with height and BMI were not replicated with N = 119,206 partici-
pants (p = 0.21) [23] and N = 112,363 (p = 0.17) [24], respectively. Review of both the BMI and
height studies failed to identify any variants within 1 Mb of the p.Ile684Ser variant that could
explain the association of this variant with height and BMI that we observed. The association
with IBD was previously reported (OR = 1.16; p-value = 4.3x10-16) [11]. In addition to the sig-
nificant association with risk of more severe acne as a teenager, we observed an association
with risk of severe acne with a q-value just exceeding the 0.05 threshold (OR = 1.07; q = 0.056).
This variant was evaluated for association with risk of acne vulgaris in 1893 cases and 5132
controls and was found to be modestly associated (OR = 1.135; 95% CI [1.0048, 1.283];
p = 0.045) [17, 18]. An association with protection from psoriasis has been reported in the lit-
erature (OR = 0.71; p = 4.00x10-11) [21] but not found in this dataset (OR = 0.95; q = 0.20)
despite 80% power to identify a protective association with an OR less than 0.92 (S7 Table). A
previous, smaller PheWAS study of rs12720356 in 29,377 European participants for 502 com-
mon and 30 clinical traits related to TYK2 biology did not identify any significant associations
[20].
Discussion
Our PheWAS study of variants in the Th17 and IL-17 pathway rediscovered known and iden-
tified novel significant associations which provide insight into conditions that may be affected
by modulation of the protein encoded by the gene. We reviewed results for the four variants
that appear to have an effect on human clinical traits, to assess possible interpretations of the
PheWAS findings [25]. Considering the results for the variant encoding p.Arg381Gln in IL23R
gene, we noted that Il-23R and Th17 cytokines are down-regulated after successful therapies
and there are monoclonal antibodies directed against IL-12/23p40, IL-17A and IL-17RA
Phenome-wide association study of Th17 IL-17 pathway genes
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which are effective in psoriasis [1, 26]. In addition to psoriasis, therapies directed against IL23
have been tested in other diseases including psoriatic arthritis, multiple sclerosis and Crohn’s
diseases [1]. The association with decrease in dandruff frequency is likely to be due to true plei-
otropy since Di Meglio et al [10] showed that the individuals homozygous for the Arg381Gln
allele in Il23R gene were strikingly unresponsive to IL-23, with minimal or no IL-17A and IL-
17F production suggesting a shared biological mechanism, and we did not observe correlation
between the associated traits of dandruff frequency, Crohn’s disease and psoriasis.
The PheWAS results for RORC regulatory variant highlighted associations for the minor
allele with protection from allergies, a phenotype that has not been comprehensively studied
using a whole genome scan approach. Multiple companies have programs targeting RORC
including Vitae Pharmaceuticals with a phase II program in psoriasis, and Japan Tobacco with
a phase I program for autoimmune and allergic asthma (Pharmaprojects: https://citeline.com/
products/pharmaprojects/). If rs4845604 is shown to be associated with reduced levels of the
RORγT transcript, then a RORC inhibitor may be an effective treatment for diseases for which
this variant has a protective effect, such as asthma.
The PheWAS results for the variant encoding p.Ile684Ser in TYK2 (which we noted was
working through the ICAM1 gene) highlighted a known risk association with IBD and a pro-
tective association for psoriasis. While there are no marketed drugs targeting ICAM1, efalizu-
mab is an integrin alpha-L/beta-2 inhibitor which was approved for the treatment of psoriasis
but then withdrawn due to a potential risk to patients of developing progressive multifocal leu-
koencephalopathy (FDA. Efalizumab withdrawal. 2009 [updated 11 Apr 2011] http://www.fda.
gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm143347.
htm). The integrins and their receptors potentially represent a class of targets of interest for
inflammatory and immune diseases.
While our study is not a comprehensive evaluation of the Th17 pathway, the results high-
lighted that the promoter variant, rs2275913, in IL17A and variant encoded by p.Gln484STOP
in IL17RB are unlikely to have a functional impact on the human traits studied since they are
either not associated or associated with a small number with good power while the variant
encoding p.Arg381Gln in IL23R, regulatory variant, rs4845604, in RORC, variant encoding p.
Asp10Asn in TRAF3IP2 and variant encoding p.Ile684Ser in TYK2 do show evidence that they
have an impact on human traits with multiple trait associations. The TRAF3IP2 and TYK2
genes impact downstream or more distal signaling and we observed both protective and risk
associations with variants in these genes. In contrast, the IL23R and RORC genes have a more
direct impact on IL-17 levels and we observed only protective trait associations for these genes.
The strategy provides a more holistic view of the impact of gene variation across the pathway
that is not as apparent when genes are evaluated one at a time.
Analysis of these data provided insight into the use of self-reported data. These data
included traits that have not been previously studied using a genome scan approach such
as dandruff frequency, as well as infection traits like strep throat occurrences. The results
obtained using the self-reported data are similar to association results reported by cohort stud-
ies (which focus on clinically assessed patients). One example is illustrated by the results for
the variant encoding p.Asn10Asp in TRAF3IP2. While associations with psoriasis and IBD
were reported, the results failed to identify a statistically significant association with psoriatic
arthritis–reported as p = 1.13x10-20 with OR = 1.95 [14]. Psoriatic arthritis is relatively uncom-
mon (prevalence is estimated to vary from 0.3% to 1%). In this dataset we observed a higher
than expected prevalence of reported cases in the 23andMe community (1.3%) which may be
due to customer misreport, use of inconsistent diagnostic criteria compared to past GWAS
cohorts (which used the CASPAR and Moll and Wright criteria [14]), and/or differences in
disease spectrum in the 23andMe cohort compared to other clinically ascertained cohorts.
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In summary, we were able to confirm numerous reported associations and extend our find-
ings of variants in the TH17 pathway. Specifically, we characterized a regulatory variant in
RORC gene associated with multiple allergy traits and asthma related traits which have not been
reported previously. We identified that the Ile684Ser variant within the TYK2 gene, which may
act through the ICAM1 gene, is associated with many traits including psoriasis, Crohn’s disease,
and infections, and may suggest integrins and their receptors as potential drug targets. Addi-
tional associations, beyond those reported in the literature, were observed for the variants with
previous association reports suggesting this information provides valuable information about
the effect of the variant on human traits. This PheWAS study provided a comprehensive profile
of human traits associated with each variant evaluated, including skin, infection and allergy
traits, which haven’t been comprehensively studied thus far. This PheWAS does have limita-
tions. Important variants or genes may not have been included in this study which was limited
to 7 variants in 7 different genes. The analyses were well powered for moderate and large effect
sizes greater than 1.5 for nearly 80% of the traits for all variants reported in European partici-
pants but samples sizes were too small to provide a meaningful analysis for other ethnicities and
traits. The use of PheWAS in the drug discovery context provides an approach for identifying
variants most likely to have an observable effect on gene function and context for the direction
of effects suggesting whether a gene activator or inhibitor is needed. Furthermore, clinical trials
may want to select or eliminate patients carrying variants with an effect on gene function for
drug target genes depending on size and direction of the effect. Interpretation of PheWAS study
findings can be complicated by nearby genes, as illustrated by the association of RORC and hair
curl, and variable power for each trait assessed. We hope that the emergence of EMR-linked
biobanks with genetic data will facilitate more routine use of the PheWAS screen providing
insights into drug development strategies for targeting these genes and pathways.
Methods and materials
All research participants included in the analyses provided informed consent and answered
surveys online according to 23andMe’s human subject’s protocol, which was reviewed and
approved by Ethical & Independent Review Services, a private institutional review board
(http://www.eandireview.com).
Informed consent is neither written nor oral—it is electronic. 23andMe customers consent
to participate in research online and consent is captured electronically. Ethical & Independent
Review Services approved this form of informed consent and waived the requirement to obtain
signed consent under 45 CFR 46.117(c). Participants have access to all consent documents
through their accounts and may change their consent selection at any time.
Samples were genotyped on one of four genotyping platforms. The genotyping platforms,
quality control procedures, ancestry determination and imputation protocols have been previ-
ously described [27]. Restriction to greater than 97% European ancestry excluded about 25%
of otherwise eligible research participants. Minor allele frequencies (MAF) for the variants
included in this study for each genotyping platform are listed in S10 Table.
We tested the association with 1254 well-curated phenotypes, which are distributed among
different phenotypic categories (e.g., cognitive, autoimmune, psychiatrics, etc). An overview of
the trait data collection process has been previously described [12]. Specific definitions for all
traits associated with variants with q<0.05 FDR are summarized in S1 Appendix. For case con-
trol comparisons, we computed association test results by logistic regression. For quantitative
traits, association tests were performed by linear regression. For survival traits, we computed
association test results by fitting Cox proportional hazards regression. All regression analyses
were performed using R version 3.2.2. We typically assumed additive allelic effects and
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included covariates for age (as determined by participant date of birth), gender, and the top
five principal components to account for residual population structure. The association test P
value we report was computed using a likelihood ratio test.
Power calculations were performed for binary and continuous traits estimating the mini-
mum OR or effect size (β) in response standard deviations per allele to identify associations
using logistic or linear regression, respectively, with an additive model assuming the given
sample size, 80% power, minor allele frequencies corresponding to the variants selected (0.05–
0.35) and β = 0.0002 which empirically corresponds to the FDR cut-off of 5% in these results.
For each allele frequency, the proportion of traits (of 1250 binary or continuous traits) with
power to identify small OR and effect sizes (OR>1.15; β>0.06), moderate OR and effect sizes
(OR>1.5; β>0.11) and large OR and effect sizes (OR>2; β>0.15) is calculated. The OR ranges
were determined based on the 25th, 50th, and 75th quantiles of the ORs and hazard ratios from
the GWAS catalog with p-values 5x10-8 for non-pharmacogenetic and non-anthropometric
traits [28]. The effect size ranges were selected so that the distribution of effect sizes within the
small, moderate and large effect size range was similar to that for the odd ratios. Correlation
between traits involved in associations with FDR less than 5% was summarized using the Pear-
son correlation coefficient. Welch’s t-test is used to test for consistency of OR estimates using
OR estimates, confidence intervals and sample sizes.
Supporting information
S1 Fig. Pearson correlation coefficients for associated traits. Pearson correlation coefficients
for traits associated with traits at 5% FDR.
(TIF)
S1 Table. Th17 and IL-17 pathway genes. List of genes evaluated as associated with Th17 and
IL-17 pathway (Wikipathways https://www.wikipathways.org and pathway knowledge)
(XLSX)
S2 Table. Previously reported genetic associations. Variants evaluated and traits reported as
associated by combining data from multiple sources including the National Human Genome
Research Institute (NHGRI) GWAS Catalog, the tables and supplementary materials of manu-
scripts archived in the NHGRI GWAS Catalog, and the database of Genotypes and Phenotypes
(dbGaP), among others [5].
(XLSX)
S3 Table. Study association statistics. Association statistics (trait, description, gene, rs num-
ber, p-value, experiment wide q-value, number of cases, number of controls, OR and 95%
confidence interval, number of participants, effect size and 95% confidence interval) from
23andMe analysis for traits with FDR significance level of 5%. We report OR for binary traits
and effect sizes for quantitative traits including some traits that analyzed ordinal numbers.
(XLSX)
S4 Table. Study association statistics. Association statistics (trait, description, gene, rs num-
ber, p-value, experiment wide q-value, number of cases, number of controls, OR and 95%
confidence interval, number of participants, effect size and 95% confidence interval) from
23andMe analysis for traits and levels of significance. We report OR for binary traits and effect
sizes for quantitative traits including some traits that analyzed ordinal numbers.
(XLSX)
S5 Table. Study and literature association results. Summary of association statistics (p-val-
ues, OR, 95% confidence intervals and sample sizes) for results from this study and from the
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literature with references.
(XLSX)
S6 Table. Comparison of effect sizes for immune traits. Summary of p-values for Welch’s t-
test which was used to test for consistency of OR estimates. Ratio of odd ratios and 95% CI is
for effect estimates from this study verses previously reported associations.
(XLSX)
S7 Table. Power table for each variant and phenotype. Maximum OR and effect size where
there is 80% power to identify an effect assuming an additive model, β = 0.0002, and given
number of cases and controls or N and given allele frequency.
(XLSX)
S8 Table. Power summary for each variant. Summary of the proportion of traits with 80%
power to detect small, moderate and large effects for each variant.
(XLSX)
S9 Table. Number of cases for eMERGE PheWAS study. The number of cases for pheno-
types of interest in a PheWAS [7].
(XLSX)
S10 Table. MAF stratified by array. Minor allele frequencies for all variants for each genotyp-
ing array.
(XLSX)
S1 Appendix. Phenotype definitions. Survey names, survey questions, and logic used to
define cases and controls for traits associated with variants with q<0.05 FDR.
(PDF)
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